about
Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained.Non-healthcare costs of hepatitis C: A systematic review.What is the social cost of injured people in traffic collisions? An assessment for Catalonia.Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995-2007.Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.Income transfer policies and the impacts on the immunization of children: the Bolsa Família Program.[Health care financing: is it enough and appropriate?].The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients.Does €1 Per Prescription Make a Difference? Impact of a Capped Low-Intensity Pharmaceutical Co-Payment.Does MCDA Trump CEA?De la utilidad de los medicamentos al valor terapéutico añadido y a la relación coste-efectividad incremental[Cost-benefit analysis]Cost accounting and public reimbursement schemes in Spanish hospitals[Review of the scientific evidence of the efficiency of erythropoietin use]Cost efficiency in primary care contracting: a stochastic frontier cost function approach[Why we shouldn't be afraid of cost sharing][Economic evaluation of health interventions: the opportunity cost of not evaluating]Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic reviewAuthors' Reply to Angelis and Kanavos: "Does MCDA Trump CEA?"
P50
Q37397788-0B4DCC07-C8BC-44E6-8C7B-B8C28F3E3F60Q38606907-7FA842A5-FF29-4E0F-8BFB-81BD237A6D89Q43408063-1A2317F4-C731-4431-8A34-7CA8EE08C7F8Q44609252-418E777D-E3D3-4851-BDD1-195D812C783DQ44929812-51F14AAB-8C69-4F67-8B15-711610A5AE39Q45428430-BC9E4402-D3E5-4A21-930E-FA27AAA69A43Q50778774-378A2B43-74A4-44F0-9FDB-DFEE1BF6ECB5Q51151532-BA5BD21A-28FC-482C-9548-DEDB216A70D5Q51687780-DA60F815-C778-4B61-B4F6-80C1CBA05F3AQ51739057-0FCF2336-9F60-4005-B940-7AB90411B47EQ53827953-7D14C639-58F6-417A-A566-7B88D11C0976Q57753791-595ABBD4-D29C-4C72-BE09-FEBECB3AD5BCQ74042299-41F4ED9F-867A-4309-A751-20205D22385EQ79177905-A89B482C-696F-4E3E-9F87-07FAB7F24034Q79187423-13036C71-1761-4CC6-B1E7-A21F8EAF2695Q80603288-79F4825E-DEF8-487A-B652-8DF87A3CBE74Q83295220-F3FE964F-4DC2-437D-97BC-185301E0AFBCQ84601055-F7D3B9EB-80B5-4907-923F-1025C7EBE643Q84817893-4E08CA85-52A1-4F61-AC70-31A1143E89DFQ91810277-681315ED-8AC1-42B6-82BD-07F9AA2B55EFQ93260249-4E911A41-05B7-4D4E-85FA-BE0AD9984AF8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Jaume Puig-Junoy
@ast
Jaume Puig-Junoy
@en
Jaume Puig-Junoy
@es
Jaume Puig-Junoy
@nl
Jaume Puig-Junoy
@sl
type
label
Jaume Puig-Junoy
@ast
Jaume Puig-Junoy
@en
Jaume Puig-Junoy
@es
Jaume Puig-Junoy
@nl
Jaume Puig-Junoy
@sl
prefLabel
Jaume Puig-Junoy
@ast
Jaume Puig-Junoy
@en
Jaume Puig-Junoy
@es
Jaume Puig-Junoy
@nl
Jaume Puig-Junoy
@sl
P214
P227
P950
P1053
D-7047-2013
P106
P1580
P21
P213
0000 0003 6809 0893
P214
P227
P31
P3829
P496
0000-0003-1695-3108
P569
1959-01-01T00:00:00Z
P735
P7859
lccn-no2001034392